Found 26 results in Building Products

Quality by Design (QbD) is well established in the pharmaceutical industry for manufacturing processes, including active pharmaceutical ingredients and drug products.

Read this case study to learn how a team of bioavailability experts at Catalent took a target molecule from early stage to Phase 1 in under nine months.

Read this case study to learn about how Catalent deployed its integrated OneXpress® Solution to expedite the transfer of a partner program to one of its late-stage manufacturing sites while optimizing the utilization of a limited supply of API.

By taking advantage of modern screening technologies to collect and leverage molecular data early on, drug developers can bridge the gap between molecule discovery and dose form selection.

This eBook is a selection of articles published in the Journal of Drug Delivery Science and Technology, giving overviews on different types of strategies that are used to increase the dissolution rates of poorly water-soluble drugs in order to increase their bioavailability.

API-sparing development techniques and identification of the appropriate scalable formulation technology to improve drug solubility and enhance oral bioavailability can help increase your chances of success when moving from preclinical development to early phase clinical trials.

This eBook will explore how to drive excellence within the forecasting process and how to utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines and to identify potential supply-related issues before they negatively impact your study.

Learn how to leverage the drug development knowledge and build a strategy that maintains the integrity, quality, and timeliness of the manufacturing process.

Understanding and planning for phase-appropriate CMC-related activities can facilitate the transition from early development through commercialization.

Summary: In this webinar a group of experienced cancer drug developers discusses key strategies in managing an orphan drug program.